Safety and efficacy of intranasal insulin in patients with Alzheimer's disease: a systematic review and meta-analysis.
Alzheimer’s disease
intranasal insulin
mild cognitive impairment
Journal
Journal of clinical and translational research
ISSN: 2424-810X
Titre abrégé: J Clin Transl Res
Pays: Singapore
ID NLM: 101667205
Informations de publication
Date de publication:
31 Aug 2023
31 Aug 2023
Historique:
received:
18
01
2023
revised:
28
02
2023
accepted:
23
03
2023
medline:
11
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
We performed this meta-analysis to evaluate the safety and efficacy of intranasal insulin in Alzheimer's disease (AD) patients. A literature search was conducted for PubMed, Scopus, and Web of Science from inception until August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios or mean difference (MD) in the meta-analysis models using Review Manager (RevMan version 5.4). Our results from 12 studies favored intranasal insulin over placebo in terms of Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-cog) 20 IU, (MD = -0.13, 95% CI [-0.22, -0.05], Ultimately, this meta-analysis showed that intranasal insulin in small doses (20 IU) significantly affects patients with AD. Further studies are recommended on reliable insulin delivery devices to increase insulin in the central nervous system. Intranasal insulin has shown promising results in treating patients with AD. The lower doses (20 IU) can play a positive role in improving the disease. As research continues, it is likely that this treatment will become more widely accepted and utilized in clinical practice.
Sections du résumé
Background and Aim
UNASSIGNED
We performed this meta-analysis to evaluate the safety and efficacy of intranasal insulin in Alzheimer's disease (AD) patients.
Methods
UNASSIGNED
A literature search was conducted for PubMed, Scopus, and Web of Science from inception until August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios or mean difference (MD) in the meta-analysis models using Review Manager (RevMan version 5.4).
Results
UNASSIGNED
Our results from 12 studies favored intranasal insulin over placebo in terms of Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-cog) 20 IU, (MD = -0.13, 95% CI [-0.22, -0.05],
Conclusion
UNASSIGNED
Ultimately, this meta-analysis showed that intranasal insulin in small doses (20 IU) significantly affects patients with AD. Further studies are recommended on reliable insulin delivery devices to increase insulin in the central nervous system.
Relevance for Patients
UNASSIGNED
Intranasal insulin has shown promising results in treating patients with AD. The lower doses (20 IU) can play a positive role in improving the disease. As research continues, it is likely that this treatment will become more widely accepted and utilized in clinical practice.
Identifiants
pubmed: 37564252
pii: jctres.09.202304.23-00013
pmc: PMC10411979
Types de publication
Journal Article
Review
Langues
eng
Pagination
222-235Informations de copyright
Copyright: © 2023 Author(s).
Déclaration de conflit d'intérêts
All authors have no conflicts of interest.
Références
Arch Neurol. 2012 Jan;69(1):29-38
pubmed: 21911655
Neurology. 2008 Feb 5;70(6):440-8
pubmed: 17942819
J Alzheimers Dis. 2019;69(2):489-498
pubmed: 30958348
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Mol Neurobiol. 2013 Feb;47(1):145-71
pubmed: 22956272
J Alzheimers Dis. 2017;57(4):1325-1334
pubmed: 28372335
Drugs Aging. 2021 May;38(5):407-415
pubmed: 33719017
J Alzheimers Dis. 2015;44(3):897-906
pubmed: 25374101
JAMA Neurol. 2020 Sep 1;77(9):1099-1109
pubmed: 32568367
Diabetes Obes Metab. 2018 Oct;20(10):2467-2471
pubmed: 29790638
J Alzheimers Dis. 2014;40(4):967-79
pubmed: 24531162
Exp Gerontol. 2022 Jul;164:111812
pubmed: 35476966
Eur J Epidemiol. 2018 Jul;33(7):635-644
pubmed: 29572656
Am J Med. 2018 Oct;131(10):1161-1169
pubmed: 29425707
J Neurosci. 2001 Apr 15;21(8):2561-70
pubmed: 11306609
Sci Rep. 2022 Jan 25;12(1):1346
pubmed: 35079029
CNS Drugs. 2014 Dec;28(12):1185-9
pubmed: 25373630
Neurobiol Aging. 2006 Mar;27(3):451-8
pubmed: 15964100
Neurology. 1998 Jan;50(1):164-8
pubmed: 9443474
Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1971-6
pubmed: 19188609
Diabetologia. 2010 Aug;53(8):1743-53
pubmed: 20424816
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Histol Histopathol. 2022 May;37(5):431-439
pubmed: 35040114
Neurobiol Aging. 2009 Mar;30(3):377-87
pubmed: 17692997
Front Neurol. 2021 Oct 12;12:719849
pubmed: 34712197
Int J Mol Sci. 2022 Apr 22;23(9):
pubmed: 35563031
Int J Mol Sci. 2021 Dec 09;22(24):
pubmed: 34948054
Life Sci. 2022 Jun 15;299:120538
pubmed: 35395244
J Alzheimers Dis. 2013;35(4):789-97
pubmed: 23507773
J Alzheimers Dis. 2008 Apr;13(3):323-31
pubmed: 18430999
Expert Opin Drug Deliv. 2022 Jan;19(1):87-102
pubmed: 35040728
J Cereb Blood Flow Metab. 2015 Mar;35(3):371-81
pubmed: 25492117